EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES
Subrata Ghosh 1
Marc Ferrante 2
Britta Siegmund 3
Takehiro Arai 4
Walter Reinisch 5
Naomi Martin 6
Joanne Rizzo 6
Kristina Kligys 6
Yafei Zhang 6
Javier Zambrano 6
Jasmina Kalabic 7
David P. Hudesman 8
Edouard Louis 9
1 University College Cork, Birmingham, Ireland
2 University Hospitals Leuven, Leuven, Belgium
3 Charité - Universitätsmedizin Berlin, Berlin, Germany
4 Tokatsu‐Tsujinaka Hospital, Chiba, Japan
5 Medical University of Vienna, Wien, Austria
6 AbbVie, Inc, North Chicago, United States
7 AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany
8 Inflammatory Bowel Disease Center, New York, United States
9 CHU Liège and Liège University, Liège, Belgium
Topic
Endoscopy, Histopathology, IBD
Session
IL-23-Blockers in IBD: Part 2
Conference
UEG Week Copenhagen 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]